Celgene Corp. has completed its acquisition of Avila Therapeutics for $350 million in cash, with as much as $575 million more contingent upon AVL-292 milestones and candidates from Avila’s discovery program.   Celgene gains a highly-selective Bruton’s tyrosine kinase inhibitor currently in Phase I development, as well as the Avilomics discovery platform for developing targeted covalent drugs that treat diseases through protein silencing.   “The Avilomics research team brings to Celgene an exciti...